biOasis Technologies Inc, a biopharmaceutical company focused on drug-delivery across the brain-blood barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the agreement, MedImmune will evaluate the therapeutic effect of its preclinical assets with  biOasis's Transcend brain-delivery platform.
 
“Our working relationship with MedImmune began in November 2012. In our collaboration, we demonstrated transport of MedImmune's antibodies into the brain using our first-generation Transcend vector,” said Reinhard Gabathuler, chief scientist at biOasis, in a press release. “In addition, we introduced our second-generation Transcend vector into this collaboration and other programs we have underway, where we have observed equivalent or increased antibody transport into the brain. We feel that this next generation of Transcend will have specific advantages in transporting certain biologics into the brain.”  

Financial terms were not disclosed.

Source: biOasis Technologies